Clinical trials: IPMN, active
IPMN, IPMN, Pancreatic
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
- Trial name
- NCT04207944
- Testing
- Sulindac 400 MG
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Duke University
IPMN, Pancreatic
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare.
- Trial name
- INCITE (NCT06694792)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas
Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Intraepithelial Neoplasia
- Trial name
- B-PDAC (NCT07709052)
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Neoplasm of Pancreas, IPMN, Pancreatic
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous…
- Trial name
- NCT06519097
- Testing
- Vitamin E Delta Tocotrienol
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cyst, Pancreas Cyst
Feasibility of Molecular Biology in Pancreatic Cyst Tumors
The main objective of the study is to compare the diagnostic accuracy of intra-cystic fluid DNA molecular analysis to standard diagnostics.
- Conditions
- Pancreatic Cyst, Pancreas Cyst, Serous Cystadenoma, Mucinous Cystadenoma
- Trial name
- CYST-GEN (NCT03305146)
- Testing
- Molecular biology analysis of pancreatic intra-cyst fluid
- Where
- 11 sites in France
- Volunteers
- 93 people
- Sponsor
- Hospital St. Joseph, Marseille, France
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Intraductal Papillary Mucinous Neoplasm of Pancreas
Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts
The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary…
- Trial name
- NCT06162468
- Testing
- Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel
- Where
- 2 sites in New Zealand
- Volunteers
- 20 people
- Sponsor
- University of Auckland, New Zealand
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
Pancreatic Cancer, Chronic Pancreatitis
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma
The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older.
- Conditions
- Pancreatic Cancer, Chronic Pancreatitis, Intraductal Papillary Mucinous Neoplasm, Mucinous Cystic Neoplasm
- Trial name
- NCT07875582
- Testing
- Blood-Based Protein Biomarker Assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
IPMN, Pancreatic
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Intraductal papillary mucinous neoplasms (IPMN) are one of the main precursor lesions of pancreatic ductal adenocarcinoma (PDAC), a lethal disease predicted to become the second leading cause of cancer-related deaths in Western…
- Trial name
- NCT06574373
- Testing
- Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention
- Where
- 2 sites in Italy
- Volunteers
- 3,600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Cyst
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria.
- Trial name
- CLIMB (NCT03492151)
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreas Cancer, Exosomes
ExoLuminate Study for Early Detection of Pancreatic Cancer
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
- Trial name
- NCT05625529
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Biological Dynamics
IPMN, Pancreatic, IPMN
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure.
- Trial name
- MAPS (NCT05117723)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- St Vincent's Hospital Melbourne
Intraductal Papillary Mucinous Neoplasm
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
- Trial name
- NCT05433935
- Testing
- Observation
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Intraductal Papillary Mucinous Neoplasms, Pancreatic Exocrine Insufficiency
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk.
- Trial name
- IPEX (NCT07535125)
- Volunteers
- 600 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Neoplasms
Real-Time AI During Pancreatoscopy for Detection of Pancreatic Neoplasia
This prospective pilot study will evaluate the diagnostic performance of a previously validated artificial intelligence (AI) model when applied in real time during digital per-oral pancreatoscopy (POPS).
- Trial name
- NCT07809841
- Testing
- AIWorks-Cholangioscopy Real-Time Artificial Intelligence Model
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Diabetes, IPMN, Pancreatic
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g.
- Conditions
- Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- LASERBLOOD (NCT07659639)
- Testing
- Diagnostic procedures
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Whipple Operation
Dachengqi Decoction for Enhancing Early Gastrointestinal Recovery After Whipple Surgery
To investigate the clinical efficacy of the traditional Chinese medicine formula Dachengqi Decoction in promoting early gastrointestinal function recovery after Whipple surgery, and to evaluate its impact on postoperative…
- Trial name
- NCT06948474
- Testing
- Dachengqi decoction, modified gastrointestinal dual-lumen feeding tube, Normal Saline (0.9% NaCl)
- Where
- China
- Volunteers
- 45 people
- Sponsor
- China-Japan Friendship Hospital